Cargando…

Fixed-Ratio combinations (Basal Insulin Plus GLP-1RA) in Type 2 diabetes. An analytical review of pivotal clinical trials

In type 2 diabetes, therapeutic failure to the oral anti diabetics is frequent, the use of schemes with basal insulin or with multiple doses of insulin (basal insulin and short-acting insulins) are a widely accepted way to intensify therapy. The use of GLP-1 receptor agonists is another intensificat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vargas-Uricoechea, Hernando, Frias, Juan Pablo, Vargas-Sierra, Hernando David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SBDR - Society for Biomedical Diabetes Research 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082333/ https://www.ncbi.nlm.nih.gov/pubmed/37185053 http://dx.doi.org/10.1900/RDS.2023.19.14

Ejemplares similares

Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
por: Vargas-Uricoechea, Hernando
Publicado: (2022)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
por: Vargas-Uricoechea, Hernando
Publicado: (2018)

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2017)

Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia
por: Suastika, Ketut, et al.
Publicado: (2022)

Molecular Mechanisms in Autoimmune Thyroid Disease
por: Vargas-Uricoechea, Hernando
Publicado: (2023)

Vitamin D nutritional status in the adult population in Colombia – An analytical cross-sectional study
por: Hernando, Vargas-Uricoechea, et al.
Publicado: (2020)

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
por: Blonde, Lawrence, et al.
Publicado: (2020)

Population Status of Vitamin B12 Values in the General Population and in Individuals with Type 2 Diabetes, in Southwestern Colombia
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2023)

Control of Blood Pressure and Cardiovascular Outcomes in Type 2 Diabetes
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2018)

The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
por: Liu, Jhih-Syuan, et al.
Publicado: (2023)

Concordance between the TIRADS ultrasound criteria and the BETHESDA cytology criteria on the nontoxic thyroid nodule
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2017)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Real‐world effectiveness and safety of insulin glargine 300 U/ml in insulin‐naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS
por: Vargas‐Uricoechea, Hernando, et al.
Publicado: (2022)

LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin
por: Hoog, Meredith, et al.
Publicado: (2022)

Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
por: Miura, Hiroshi, et al.
Publicado: (2022)

The Usefulness of Thyroid Antibodies in the Diagnostic Approach to Autoimmune Thyroid Disease
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2023)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
por: Moreira, Rodrigo Oliveira, et al.
Publicado: (2018)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes
por: Gomez‐Peralta, Fernando, et al.
Publicado: (2021)

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
por: Frias, Juan P., et al.
Publicado: (2018)

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
por: Balena, R, et al.
Publicado: (2013)

Population Status of Iodine and Its Potential Effects on Thyroid Function and Autoimmunity in Southwestern Colombia
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2022)

Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes
por: Nomoto, Hiroshi
Publicado: (2023)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans
por: Hansen, Jakob Schiøler, et al.
Publicado: (2015)

Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
por: Posso-Osorio, Iván, et al.
Publicado: (2023)

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting
por: Drummond, Russell, et al.
Publicado: (2018)

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
por: McCrimmon, Rory J., et al.
Publicado: (2022)

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
por: Skolnik, Neil, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g9jtd51fgl2fk0nupe4bleffhn